Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Mol Biosyst. 2012 Oct;8(10):2523–2526. doi: 10.1039/c2mb25099c

Fig. 1.

Fig. 1

Evaluation of biochemical and cellular activities of Mps1-IN-BODIPY and BI-BODIPY against their respective kinase targets. (A) Conjugation to BODIPY reduces the affinity of Mps1-IN for Mps1. Inhibition of Mps1 by Mps1-IN-1 and Mps1-IN-BODIPY was measured by LanthaScreen™ Kinase assay (LifeTechnologies). (B) BI2536 and BI-BODIPY exhibit similar inhibitory activities against recombinant PLK1, PLK2, and PLK3 kinases. Inhibition of PLK1, PLK2, and PLK3 by BI2536 and BI-BODIPY were measured by Z´-Lyte™ kinase assay (Life Technologies). (C) Western blot for cyclin B indicates that BI-BODIPY induces cell cycle arrest at concentrations comparable to the parent inhibitor, BI2536.